Low Molecular Weight Heparin-Induced Thrombocytopenia: A Case Series Study of Newly Admitted Hemodialysis Patients

IF 1.2 4区 医学 Q3 UROLOGY & NEPHROLOGY Hemodialysis International Pub Date : 2025-02-17 DOI:10.1111/hdi.13206
Hui Ren, Wei Liang, Aihong Wang, Zibo Xiong, Guang Yang
{"title":"Low Molecular Weight Heparin-Induced Thrombocytopenia: A Case Series Study of Newly Admitted Hemodialysis Patients","authors":"Hui Ren,&nbsp;Wei Liang,&nbsp;Aihong Wang,&nbsp;Zibo Xiong,&nbsp;Guang Yang","doi":"10.1111/hdi.13206","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Low molecular weight heparin (LMWH), a common anticoagulant in hemodialysis, can cause the dangerous condition of heparin-induced thrombocytopenia (HIT) in rare cases. The present study reviews five cases of HIT diagnosed in our center, which treats more than 400 maintenance hemodialysis patients annually over a 30-year period. All five cases occurred in incident patients who were being exposed to LMWH for the first time. Treatment involved stopping LMWH and using alternative anticoagulants. Both the 4Ts score and antibody tests were used to confirm the diagnosis of HIT. Following diagnosis, close monitoring was performed for 10–15 days in typical cases or 30 days in severe cases until blood platelet levels recovered to near normal values. Our results suggest that while uncommon, HIT associated with use of LMWH can occur in hemodialysis patients, especially when patients are being exposed to this anticoagulant for the first time.</p>\n </div>","PeriodicalId":12815,"journal":{"name":"Hemodialysis International","volume":"29 2","pages":"242-246"},"PeriodicalIF":1.2000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hemodialysis International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hdi.13206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Low molecular weight heparin (LMWH), a common anticoagulant in hemodialysis, can cause the dangerous condition of heparin-induced thrombocytopenia (HIT) in rare cases. The present study reviews five cases of HIT diagnosed in our center, which treats more than 400 maintenance hemodialysis patients annually over a 30-year period. All five cases occurred in incident patients who were being exposed to LMWH for the first time. Treatment involved stopping LMWH and using alternative anticoagulants. Both the 4Ts score and antibody tests were used to confirm the diagnosis of HIT. Following diagnosis, close monitoring was performed for 10–15 days in typical cases or 30 days in severe cases until blood platelet levels recovered to near normal values. Our results suggest that while uncommon, HIT associated with use of LMWH can occur in hemodialysis patients, especially when patients are being exposed to this anticoagulant for the first time.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
低分子肝素诱导的血小板减少症:新入院血液透析患者的病例系列研究。
低分子肝素(LMWH)是一种常见的血液透析抗凝剂,在极少数情况下可引起肝素诱导的血小板减少症(HIT)的危险状况。本研究回顾了在我中心诊断的5例HIT病例,在30年的时间里,我中心每年治疗400多例维持性血液透析患者。所有5例病例均为首次接触低分子肝素的意外患者。治疗包括停止低分子肝素和使用替代抗凝剂。4Ts评分和抗体检测均用于确认HIT的诊断。诊断后,典型病例密切监测10-15天,重症病例密切监测30天,直至血小板水平恢复到接近正常值。我们的研究结果表明,虽然不常见,但与低分子肝素使用相关的HIT可能发生在血液透析患者中,特别是当患者首次接触这种抗凝剂时。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hemodialysis International
Hemodialysis International UROLOGY & NEPHROLOGY-
CiteScore
2.50
自引率
0.00%
发文量
58
审稿时长
6-12 weeks
期刊介绍: Hemodialysis International was originally an annual publication containing the Proceedings of the International Symposium on Hemodialysis held in conjunction with the Annual Dialysis Conference. Since 2003, Hemodialysis International is published quarterly and contains original papers on clinical and experimental topics related to dialysis in addition to the Annual Dialysis Conference supplement. This journal is a must-have for nephrologists, nurses, and technicians worldwide. Quarterly issues of Hemodialysis International are included with your membership to the International Society for Hemodialysis. The journal contains original articles, review articles, and commentary to keep readers completely updated in the field of hemodialysis. Edited by international and multidisciplinary experts, Hemodialysis International disseminates critical information in the field.
期刊最新文献
Issue Information Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease–Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis-Stimulating Agent Dose Determination of Compassion Fatigue and Brain Fog Levels and Associated Factors Among Hemodialysis Unit Professionals: A Descriptive and Analytical Study Patients' Perspectives and Experiences of Cannabinoids to Manage Symptoms of Chronic Kidney Disease: An In-Depth Interview Study Water Distribution Systems for Hemodialysis: Design and Materials
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1